预约演示
更新于：2026-10-26
Cariprazine hydrochloride
盐酸卡利拉嗪
更新于：2026-10-26
概要
基本信息
药物类型 小分子化药 |
别名 cariprazine、Cariprazine hydrochloride (JAN/USAN)、SYMVENU + [15] |
作用方式 激动剂、拮抗剂、部分激动剂 |
作用机制 5-HT1A receptor激动剂(5-羟色胺1A受体激动剂)、5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor部分激动剂(多巴胺D2受体部分激动剂) |
在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H33Cl3N4O |
InChIKeyGPPJWWMREQHLQT-BHQIMSFRSA-N |
CAS号1083076-69-0 |
关联
94
项与 盐酸卡利拉嗪 相关的临床试验NCT07715253
Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia
CTRI/2026/09/118391
An Open-label, Randomized, Single-dose (Long-acting injectable) or Multiple-dose (oral) Clinical Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar in Participants with Schizophrenia - NIL
CTRI/2026/09/117973
Comparative effectiveness of cariprazine and olanzapine in first episode schizophrenia - nil
100 项与 盐酸卡利拉嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸卡利拉嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸卡利拉嗪 相关的专利（医药）
登录后查看更多信息
570
项与 盐酸卡利拉嗪 相关的文献（医药）2026-12-01JOURNAL OF AFFECTIVE DISORDERS
Efficacy, acceptability, and related outcomes of pharmacological interventions for acute bipolar mania: a systematic review and dose-related network meta-analysis across different age groups
Review
作者: Daray, Federico Manuel ; Kishi, Taro ; Di Lorenzo, Chiara ; Fornaro, Michele
BACKGROUND:
Acute bipolar mania carries negative social and economic consequences. We investigated the comparative efficacy/response/acceptability of pharmacological interventions for acute bipolar mania, considering dose effects across different age groups.
METHODS:
We conducted a network meta-analysis (NMA) to search for randomized controlled trials (RCTs) comparing pharmacological interventions with one another or placebo in acute bipolar mania patients, indexed in PubMed/MEDLINE, Embase, Web of Science, and Scopus (from inception through 2025.12.24). Co-primary outcomes were change in manic symptoms/response/and acceptability. Tolerability/remission and rate of adverse events were secondary outcomes. Confidence-In-Network-Meta-Analysis was likewise appraised.
RESULTS:
113 RCTs, encompassing 49 distinct treatment combinations, included 20,666 participants. Sensitivity analysis retaining only low-risk-of-bias studies and excluding outliers for possible effect modifiers indicated that risperidone 3 mg/day(SMD = -7.57;95%C.I. = -8.25;-5.85); tamoxifen 160 mg/day(SMD = -1.73;95%C.I. = -2.32;-1.13); rivastigmine 3 mg/day(SMD = -1.13;95%C.I. = -1.06;-0.58); haloperidol 30 mg/day(SMD = -0.96;95%C.I. = -1.25;-0.75); valproate 750 mg/day(SMD = -0.76;95%C.I. = -1.48;-0.58); tamoxifen 40 mg/day(SMD = -0.75;95%C.I. = -1.41;-0.59); celecoxib 400 mg/day(SMD = -0.74;95%C.I. = -1.20;-0.38); paliperidone extended-release 12 mg/day(SMD = -0.62; 95%C.I. = -0.91;-0.32); olanzapine 15 mg/day(SMD = -0.59;95%C.I. = -0.60;-0.38); olanzapine 20 mg/day(SMD = -0.52;95%C.I. = -0.66;-0.38); risperidone 4 mg/day(SMD = -0.53;95%C.I. = -0.76;-0.29); allopurinol 600 mg/day(SMD = -0.54;95%C.I. = -0.67;-0.22); cariprazine 12 mg/day(SMD = -0.49;95%C.I. = -0.66;-0.33); risperidone 4.2 mg/day(SMD = -0.46;95%C.I. = -0.75;-0.17); lithium 1500 mg/day(SMD = -0.42;95%C.I. = -0.57;-0.28); ziprasidone 160 mg/day(SMD = -0.49;95%C.I. = -0.68;-0.31); asenapine 20 mg/day(SMD = -0.38;95%C.I. = -0.53;-0.22); haloperidol 8 mg/day(SMD = -0.34;95%C.I. = -0.63;-0.05); aripiprazole 15 mg/day(SMD = -0.33;95%C.I. = -0.61;-0.06) outperformed placebo. Ziprasidone 160 mg/day, celecoxib 200 mg/day, asenapine 20 mg/day, and asenapine 10 mg/day proved more efficacious than placebo in children. No statistically significant differences were reported between treatments and placebo for response/remission/acceptability/tolerability, and manic/hypomanic switch. A meta-regression of efficacy effect sizes against the adapted AMSTAR-Plus content scores showed that larger SMDs were associated with lower AMSTAR scores, indicating lower study quality, warranting further caution for such large efficacy estimates.
CONCLUSIONS:
Our findings are consistent with previous NMAs and current guidelines, expanding the current knowledge base while concurrently appraising different drugs, doses, and age groups.
2026-09-01JOURNAL OF AFFECTIVE DISORDERS
Pharmacological interventions for acute major depression and bipolar depression with mixed features: A systematic review and dose-related network meta-analysis across different age groups
Review
作者: Singh, Balwinder ; Nunez, Nicolas ; Miola, Alessandro ; McIntyre, Roger S ; Frye, Mark A ; Veldic, Marin ; Di Lorenzo, Chiara ; Fornaro, Michele ; Sambataro, Fabio
BACKGROUND:
Acute mixed bipolar/major depression is relatively frequent, yet quantitative information about its pharmacological management is relatively scant, warranting network meta-analysis (NMA) of comparative efficacy/response/acceptability of pharmacological interventions accounting for dose effects across different age groups.
METHODS:
We searched PubMed/MEDLINE/Embase/Web of Science/Scopus (from database inception to 2026.05.25) for randomized controlled trials (RCTs) comparing pharmacological interventions with each other or placebo in patients with acute major depression/bipolar depression with mixed features. Co-primary outcomes were the change in depressive symptoms and response. Tolerability, acceptability, and change in manic symptoms were secondary outcomes. Confidence-In-Network-Meta-Analysis was appraised.
RESULTS:
22 studies assessed 5241 acute mixed bipolar depressed participants, whereas 13 studies encompassed 1852 acute mixed major depression patients. Sensitivity analyses, including those retaining low-risk-of-bias studies only, and excluding outliers for possible effect modifiers, indicated that asenapine-15 mg/day (SMD = -0.54; 95%C.I. = -1.06; -0.02), lurasidone-60 mg/day (SMD = -0.43; 95%C.I. = -0.72, -0.14), lurasidone-80 mg/day (SMD = -0.39; 95%C.I. = -0.55, -0.23) outperformed placebo for depressive symptoms reduction in bipolar patients. Lurasidone-60 mg/day (SMD = -0.43; 95%C.I. = -0.72, -0.14), lurasidone-80 mg/day (SMD = -0.38; 95%C.I. = -0.59, -0.17) outperformed placebo for bipolar children and adolescents. Lurasidone-40 mg/day (SMD = -0.80; 95% C.I. = -0.95, -0.65) outperformed placebo for major depression. Cariprazine-1.5 mg/day (RR = 1.23; 95%C.I. = 1.01, 1.51), cariprazine-3 mg/day (RR = 1.32; 95%C.I. = 1.08, 1.60), lurasidone-80 mg/day (RR = 1.36; 95%C.I. = 1.14, 1.63), olanzapine-12.5 mg/day (RR = 1.63; 95%C.I. = 1.07, 2.51), olanzapine-6 mg/day+fluoxetine-50 mg/day (RR = 2.61; 95%C.I. = 1.60, 4.39) outperformed placebo response in bipolar samples. Lumateperone-42 mg/day (RR = 1.61; 95%C.I. = 1.20; 2.18) outperformed placebo for major depression response. Quetiapine-530 mg/day in augmentation to mood stabilizers led to a significantly higher number of dropouts in bipolar patients than placebo. Meta-regression of the AMSTAR-Plus content score against efficacy and response measures showed that larger effect sizes (SMDs/logRRs) were associated with lower AMSTAR scores, reflecting lower study quality.
CONCLUSIONS:
Our findings are consistent with previous NMAs and current guidelines, yet they expand knowledge by concurrently appraising different drugs, doses, and age groups, and the quality of the evidence.
2026-09-01CNS DRUGS
Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence
Review
作者: Ardic, Ferhat ; Ikehara, Kenta ; Kato, Masaki ; McIntyre, Roger S ; Boucher, Matthieu ; Therrien, François ; Thase, Michael E ; Marrache, A Marilise
Anxiety symptoms are common in patients with major depressive disorder (MDD). The presence of anxiety symptoms can indicate greater depression severity, and is associated with a higher comorbidity burden, suicidality, lower levels of functioning, and poorer quality of life. The presence of anxiety identifies patients who are likely to experience significant burden from MDD despite standard treatment. Although clinical guidelines provide recommendations for adjunctive treatment in patients who have not responded to an antidepressant, there are currently limited recommendations specifically for patients with MDD and anxiety symptoms. Dysregulation of the monoamine system, notably noradrenaline (norepinephrine), serotonin, and dopamine signalling, has been implicated in the pathophysiology of MDD and of anxiety disorders, based mainly on preclinical, mechanistic and translational evidence. This review has two aims: (1) to explore the hypothetical role of monoamine signalling in patients with MDD with anxiety symptoms, and (2) to provide a comprehensive overview of clinical data for pharmacotherapies recommended for the first- and second-line adjunctive treatment of difficult-to-treat MDD, focusing on recent studies and analyses of patients with MDD with anxiety symptoms. Reviewed treatments included atypical antipsychotics (aripiprazole, brexpiprazole, olanzapine, quetiapine XR, risperidone, cariprazine), bupropion, ketamine/esketamine, lithium, mirtazapine/mianserin, modafinil, and triiodothyronine. Clinical data in patients with MDD with anxiety symptoms were scarce or lacking for olanzapine, risperidone, cariprazine, lithium, modafinil, and triiodothyronine. Aripiprazole, brexpiprazole, quetiapine XR, and ketamine/esketamine have been shown to improve depression and/or anxiety symptoms in patients with MDD with anxiety symptoms, although evidence is mainly short-term and derived from exploratory post hoc analyses of trials not designed to assess anxiety outcomes. Treatment decisions for patients with MDD with anxiety symptoms should be based on robust clinical data, and there is an unmet need for prospective clinical trials with anxiety-specific endpoints in this patient population.
382
项与 盐酸卡利拉嗪 相关的新闻（医药）2026-10-21
100 项与 盐酸卡利拉嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 重度抑郁症 | 美国 | 2022-12-16 | |
| 双相情感障碍及相关疾病 | 加拿大 | 2022-04-27 | |
| 躁郁症 | 加拿大 | 2022-04-22 | |
| 躁郁症1型 | 美国 | 2015-09-17 | |
| 精神分裂症 | 美国 | 2015-09-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心房中隔缺损 | 临床3期 | 美国 | 2022-07-07 | |
| 情绪易怒 | 临床3期 | 美国 | 2022-07-07 | |
| 急性精神分裂症 | 临床3期 | 韩国 | 2021-11-19 | |
| 自闭症谱系障碍 | 临床3期 | 美国 | 2021-02-01 | |
| 抑郁症 | 临床3期 | 保加利亚 | 2016-03-17 | |
| 抑郁症 | 临床3期 | 爱沙尼亚 | 2016-03-17 | |
| 抑郁症 | 临床3期 | 立陶宛 | 2016-03-17 | |
| 抑郁症 | 临床3期 | 波兰 | 2016-03-17 | |
| 慢性精神分裂症 | 临床3期 | 日本 | 2012-05-01 | |
| 躁狂 | 临床3期 | 美国 | 2010-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 751 | Cariprazine 1.5 mg/d + ADT | 繭遞製顧襯鑰觸齋襯廠(夢艱遞鹹築顧夢蓋鏇淵) = 簾鏇淵鬱窪艱製鹹鬱齋 鑰願遞齋壓製廠鹽夢積 (製繭夢糧壓餘襯繭顧衊, -2.5 ~ -0.1) 更多 | 积极 | 2025-04-30 | ||
Cariprazine 3.0 mg/d + ADT | 觸範壓衊齋構襯夢窪窪(遞鬱艱蓋觸艱憲衊夢廠) = 製顧窪願夢願醖繭遞鹹 繭壓鹽繭淵壓鬱醖淵淵 (顧構鹽衊觸製鬱壓糧憲, -1.0 ~ -0.1) | ||||||
NEWS 人工标引  | N/A | 116 | (women outpatients) | 鏇糧鑰艱繭窪糧醖構繭(膚鹹鏇艱製憲願鏇鏇壓) = There was a significant change from baseline in women to week 16 in the SAND scores: negative symptoms decreased by 6.2, positive symptoms decreased with 1.0, which is a remarkable, combined 7.2 drop. 淵艱願鏇艱鹹築艱積壓 (繭艱鑰淵鬱艱夢築鹹願 ) | 积极 | 2023-10-18 | |
临床3期 | 901 | placebo (Double-Blind Placebo QD) | 齋蓋鹹齋範襯選蓋鏇鹽(齋鬱蓋窪積衊鏇憲網網) = 製遞鏇齋膚齋壓願築簾 範窪鬱衊鏇鏇廠鏇廠窪 (鏇憲遞壓鹹繭鑰鏇鑰獵, 鏇願繭艱築觸鑰齋壓餘 ~ 艱憲簾鹹糧鹽齋鹽醖淵) 更多 | - | 2023-09-28 | ||
(Double-Blind Cariprazine 1.5 mg QD) | 齋蓋鹹齋範襯選蓋鏇鹽(齋鬱蓋窪積衊鏇憲網網) = 製餘選獵壓觸簾糧廠醖 範窪鬱衊鏇鏇廠鏇廠窪 (鏇憲遞壓鹹繭鑰鏇鑰獵, 鏇顧獵糧積憲觸選網齋 ~ 醖積憲糧鬱衊衊夢觸鏇) 更多 | ||||||
临床3期 | 751 | Placebo | 鬱網範簾繭艱觸醖築網(憲築鏇鹹簾夢夢範製顧) = 衊齋觸獵淵鹽窪衊網廠 獵網蓋鹽齋遞鹹憲蓋淵 (廠夢獵製鬱積鹹鹹壓獵 ) | 积极 | 2023-02-15 | ||
鬱網範簾繭艱觸醖築網(憲築鏇鹹簾夢夢範製顧) = 衊顧鬱遞夢衊壓鑰艱齋 獵網蓋鹽齋遞鹹憲蓋淵 (廠夢獵製鬱積鹹鹹壓獵 ) | |||||||
临床3期 | 759 | Placebo (Placebo + ADT) | 願膚構壓窪襯窪憲夢醖(窪構蓋鹽壓鬱夢選餘積) = 鏇醖遞獵網憲壓艱齋膚 壓齋廠糧艱憲壓獵築醖 (鬱製廠醖衊範網艱淵築, 0.70) 更多 | - | 2022-10-25 | ||
(Cariprazine 1.5 mg/Day + ADT) | 願膚構壓窪襯窪憲夢醖(窪構蓋鹽壓鬱夢選餘積) = 顧膚窪糧衊鏇網繭憲齋 壓齋廠糧艱憲壓獵築醖 (鬱製廠醖衊範網艱淵築, 0.70) 更多 | ||||||
临床3期 | 752 | Placebo (Placebo + ADT) | 觸餘廠觸餘壓選膚憲築(積觸顧網鏇夢壓網簾製) = 獵淵範顧選築夢壓遞製 壓餘繭餘蓋鬱醖遞遞襯 (膚鹹製鑰憲鑰範齋襯鑰, 0.70) 更多 | - | 2022-09-21 | ||
ADT+Cariprazine (Cariprazine 1.5 mg/Day + ADT) | 觸餘廠觸餘壓選膚憲築(積觸顧網鏇夢壓網簾製) = 壓範鹽艱獵願選衊繭鏇 壓餘繭餘蓋鬱醖遞遞襯 (膚鹹製鑰憲鑰範齋襯鑰, 0.69) 更多 | ||||||
临床3期 | 587 | Placebo (Placebo (Double-blind Treatment Period)) | 願獵齋醖夢襯夢齋鏇鹹(鑰鑰鹽窪鹽淵範簾鹽築) = 鑰願夢積製齋積餘壓網 憲觸壓鑰夢艱繭壓壓餘 (膚鑰網選製製簾醖網願, 壓壓窪遞獵築窪壓膚鏇 ~ 窪醖築觸築餘窪鹽淵簾) 更多 | - | 2022-03-08 | ||
(Cariprazine 3.0 mg/Day (Double-blind Treatment Period)) | 願獵齋醖夢襯夢齋鏇鹹(鑰鑰鹽窪鹽淵範簾鹽築) = 網衊醖範艱範廠網築構 憲觸壓鑰夢艱繭壓壓餘 (膚鑰網選製製簾醖網願, 顧廠餘網鏇壓顧廠獵築 ~ 繭簾糧鹹醖衊願餘顧衊) 更多 | ||||||
临床2/3期 | 125 | (MP-214 1.5-9mg) | 網製鏇繭顧構夢憲襯糧 = 艱範積淵衊餘餘觸積廠 蓋憲遞繭襯衊齋鹽遞餘 (淵壓鑰醖壓醖繭遞選廠, 廠窪醖齋廠鏇選醖觸築 ~ 衊鏇簾鹹築蓋鹽壓窪顧) 更多 | - | 2021-04-13 | ||
(Risperidone 2-12mg) | 網製鏇繭顧構夢憲襯糧 = 築窪製選鏇膚築蓋醖獵 蓋憲遞繭襯衊齋鹽遞餘 (淵壓鑰醖壓醖繭遞選廠, 鹽築淵顧積範繭鑰窪鬱 ~ 遞憲獵齋積獵願廠願憲) 更多 | ||||||
临床2/3期 | 42 | 簾窪願範淵窪襯遞餘鹽 = 獵襯壓積積鬱鏇夢夢鬱 製鑰壓憲築醖積獵襯範 (獵壓獵鏇構蓋範網艱築, 簾廠繭願獵壓鹽構範糧 ~ 壓齋鑰壓顧糧鹽糧憲鏇) 更多 | - | 2021-04-13 | |||
临床2/3期 | 254 | (MP-214 3mg) | 築獵糧壓鹽襯襯餘廠鬱 = 糧網鏇鬱廠鏇積鑰齋範 鹹願獵範構鬱夢鹽鬱鏇 (憲鹽醖築窪壓憲壓淵窪, 簾顧齋遞膚鹹醖淵鬱壓 ~ 淵襯齋積鑰網製積範製) 更多 | - | 2021-04-12 | ||
(MP-214 6mg) | 築獵糧壓鹽襯襯餘廠鬱 = 觸鬱鹽夢膚鏇獵齋構窪 鹹願獵範構鬱夢鹽鬱鏇 (憲鹽醖築窪壓憲壓淵窪, 簾鹽壓選簾膚餘積範鹹 ~ 築網膚積繭鹽獵顧蓋製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用